CHICAGO – Following up last March's investor-pleasing top-line phase III data from PERSIST-1, which tested the next-generation JAK2/FLT3 multikinase inhibitor pacritinib in myelofibrosis (MF), CTI Biopharma Corp. and partner Baxter International Inc. offered more results that better characterize the drug's position with regard to the marketed JAK2 inhibitor Jakafi (ruxolitinib), developed by Incyte Corp. and partner Novartis AG.